Jonathan Walbaum

Urology Trainee⚕️Pontificia Universidad Católica de Chile 🩺 Chile 🇨🇱

[Katy Beckermann @katy_beckermann]

Cochrane updated its PSA screening meta-analysis. 789,086 men across 6 RCTs.

➡️ PCa-specific mortality: rate ratio 0.87 (moderate certainty)

➡️ Metastatic diagnosis: RR 0.65

➡️ Adverse events / QoL: little to no difference

Why this matters: 💡 PSA screening is back on stronger evidentiary footing for disease-specific mortality. Shared decision making still drives the recommendation downstream and additional tools (biomarkers and MRI) continue to improve the gap.

https://t.co/VZk9tKRW0V

@EBMUrology #ProstateCA #Screening #Cochrane #GUonc #AUA26

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer

https://t.co/yb3G1t7bN2

Review synthesises international guidance on lutetium-177 PSMA radioligand therapy (177Lu-PSMA-RLT) in #ProstateCancer , focusing on metastatic castration-resistant disease. Major societies, including EAU, NCCN, ASCO, AUA/SUO, and CUA, endorse 177Lu-PSMA-617 after prior ARPI and taxane therapy, supported by VISION and TheraP trial data. Emerging evidence from PSMAfore is expanding use into earlier treatment settings.

Current recommendations emphasise PSMA-positive patient selection, standardised dosing, androgen deprivation therapy continuation, and multidisciplinary management.

@declangmurphy @DrMHofman @AzadOncology @RenuEapen @lawrentschuk @drMPerera

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Jonathan Walbaum @jonwalbaum]

@KotechaPinky

[Jonathan Walbaum @jonwalbaum]

Back from an amazing @APCCC_Lugano!

Special thanks to @gu_onc for the GU Cast Travel Grant and their support of the next gen of Urology! Grateful for the opportunity

Inspired by new ideas, friends and connections
A pleasure meeting @UroTeragLATAM and fellow Chilean colleagues

[OncoAlert @OncoAlert]

The #APCCC5k at #APCCC26 🇨🇭
if you didnt make it, see you at #APCCC5k in 2027‼️

@DBarreiro4 @jonwalbaum @roodvdb @AnthonyMJoshua @julired3 @swoo_rad @docheinrich @ProfKHerrmann @AarmstrongDuke
Shout out to the awesome @declangmurphy
@APCCC_Lugano
@Silke_Gillessen
@AOmlin
@weoncologists
@declangmurphy
@RenuEapen
@DrYukselUrun
@nataliagandur
@fabioturco92
@UrsulaVogl
@SScagliarini
@Tylersbrt
@neerajaiims
@amerseburger
@Cdanicas
@AarmstrongDuke
@BertrandTOMBAL
@ChrisSweens1
@EAntonarakis
@KOSJ12
@VedangMurthy
@DrRanaMcKay
@LoebStacy
@stefanofanti4
@mirrorsmed
@profkhermann
@dr_coops
@piet_ost
@_ShankarSiva
@DrSpratticus
@scocmem
@AmandaNizamMD
@tompowles1
@brian_rini
@dmukherji
@Uromigos

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ #APCCC26 Day 1 Preview — Setting the stage for key clinical decisions in prostate cancer

@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

🔹 Welcome & opening
With @Silke_Gillessen and @AOmlin
🔹 Session 1 — High-risk & locally advanced prostate cancer
Chairs: Pierre Blanchard and Edward Schaeffer

Key voices today:
André Deschamps, Glen Kristiansen, Derya Tilki, @ChrisSweens1, Jeff Michalski, @BertrandTOMBAL, @declangmurphy, Jason A. Efstathiou and @DrRanaMcKay
🔹 Key questions:
• Are we overtreating in the mpMRI / PSMA PET era?
• Which patients need ARPI + RT + long-term ADT?
• When may surgery alone be enough?
• Can genomics / AI help reduce over- and undertreatment?
• How should we treat older patients with high-risk disease?

🔹 Session 2 — PSA recurrence / persistence
Chairs: Neal Shore and Valerie Fonteyne
With Erik Briers, Jochen Walz, Pierre Blanchard, @piet_ost, @DrSpratticus, Phil Cornford, Edward Schaeffer, @KOSJ12 and Valerie Fonteyne

🔹 Key questions:
• PSA persistence or recurrence after RP — when and how to act?
• PSA recurrence after RT — when and how to act?
• Early salvage RT vs adjuvant RT
• Who may avoid imaging or treatment?
• When is metastasis-directed therapy enough?

🔹 Session 3 — mHSPC management
Chairs: Darren M. C. Poon and @ChrisSweens1
With Ana Aparicio, David Matheson, Susan Halabi, Ian D. Davis, @DrYukselUrun, Karim Fizazi / Robert J. Jones, @Tylersbrt, Joaquin Mateo and Shahneen Sandhu
🔹 Key questions:
• What subgroups matter in mHSPC today?
• Which endpoints matter most: rPFS, OS, QoL?
• Who needs TRIPLET — and who is enough with DOUBLET?
• What is the role of prostate RT?
• How should we test molecular alterations?
• Who should receive ARPI + PARPi or AKTi?
🔹 Take-home:
Day 1 is all about clinical decision-making:
who to treat, when to intensify, when to de-escalate — and how to personalize care.

@declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
#ProstateCancer #UroOncology #Oncology

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐ #APCCC26 Day 1 THE BIG CLINICAL QUESTIONS START TODAY

@OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin

Today’s agenda goes straight to the decisions we face every day in prostate cancer care:

🔹 Are we overtreating in the mpMRI / PSMA PET era?
🔹 Who really needs treatment intensification?
🔹 When can we safely de-escalate?
🔹 How should we manage PSA recurrence?
🔹 TRIPLET vs DOUBLET in mHSPC — for whom?
🔹 Can genomics, AI and biomarkers guide better decisions?
🔹 Key theme:
Not only what treatment works — but who truly needs it, when, and for how long.

@declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb
#ProstateCancer #UroOncology #Oncology

[Movember Australia @MovemberAUS]

It's Testicular Cancer Awareness Month! Do you know how your pair is hanging?

Testicular cancer is the #1 cancer among young guys but it's highly curable when caught early.

If you’ve got ’em, check your nuts.

Head to https://t.co/J99jtSDNYk to learn how.

[Tyler Seibert - tmp account. Go follow @TylerSbrt @TylerSbrt7]

🚨The sequel is here!! The other 👞 drops.

Cribriform morphology in ProtecT — now in prostatectomy specimens

#ProstateCancer #radonc #UroSoMe

@UroToday @APCCC_Lugano @PCF_Science @OncoAlert

🧵1️⃣

[Enrique Grande @drenriquegrande]

⚡️ NICE 2026 kidney cancer guideline (diagnosis & management) — updated pathway from suspicion → staging/biopsy → risk-adapted treatment & follow-up.

Striking stat: 87% of UK stage 1a RCC is diagnosed incidentally, underscoring how hard early detection is in routine practice.

#KidneyCancer @OncoAlert

https://t.co/O6xWOoleIv

[Michael Hofman @DrMHofman]

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. https://t.co/OOGooac59C

[GU Cast | Urology podcast! @gu_onc]

ICYMI, the GU Cast Live Show at #EAU26 in London now streaming on all our channels. What a fantastic evening with so many of our listeners/viewers. Thanks so much to @MaartenAlbersen @Uroweb for the invite. Enjoy the replay! @declangmurphy @RenuEapen https://t.co/AWqF3Gxvzw

[Matt Cooperberg @dr_coops]

Prof Hugosson: Göteborg trial with 30 year outcomes! NND falls to -6-, with greatest benefit for men 50-59 at randomization. Despite no image guidance, high overdx, and suboptimal tx. Best evidence we have re: the evidence for #prostatecancer screening. Get tested! #eau26 @uroweb

[Jonathan Walbaum @jonwalbaum]

In October 2025 we presented our study on the impact of Public Health Policy for Testicular Cancer in Chile at Congreso @Urolchi 2026, demonstrating improved Overall Survival after implementation.
We won best Oral presentation and today en route to #EAU26 thanks to this prize 🏆

[Dra. María Natalia Gandur Quiroga @nataliagandur]

🚨 #BladderCancer VESPER Secondary Analysis
🆕 European Urology Oncology 2026
@OncoAlert
Basal/Squamous molecular subtype emerges as the strongest prognostic factor for OS after NAC + cystectomy

N = 297 (central molecular review)

🔬 4 independent prognostic factors for overall survival:

▪ Creatinine clearance
▪ Lymphovascular invasion
▪ Perineural invasion
▪ Basal/Squamous (Ba/Sq) subtype

📊 5-year OS:
▫ 0 factors → 72%
▫ 1 factor → 67%
▫ ≥2 factors → 38%
Ba/Sq subtype showed the highest prognostic value
Independent of treatment arm (ddMVAC vs GC)
👉 Biological heterogeneity matters.
👉 Molecular stratification should inform perioperative strategy.

As immunochemotherapy expands, overtreatment risk increases.
Subtyping may help refine selection.

📖 Eur Urol Oncol 2026
https://t.co/hE1NfMuaBa
@JFontugne
Yves Allory
Stephane Culine
@HopSaintLouis
@APHP
@CancerParisNord
#MIBC #MolecularSubtyping #PrecisionOncology #Neoadjuvant #GUoncology

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs.

This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT.

And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT.

Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression.

If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics.

This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26

@UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi

[JAMA Oncology @JAMAOnc]

In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.

https://t.co/jTGubKb4Zn

[European Urology Oncology @EurUrolOncol]

Now online!

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial
by Roberto Contieri et al.

Thank you to the authors for choosing #EUO to publish your work.

Read the full article here: https://t.co/inf1JH0ttx

@uroweb
@mroupret
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@UroDocAsh
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
@RobertoContieri

[EAU Edu Platform UROONCO @EAU_Uroonco]

📰 Is audit enough to improve TURBT quality? Insights from the RESECT trial reveal improved outcomes, but can it be implemented in clinical routine? Commentary by Dr. Elisabeth Grobet-Jeandin (@elijeandin). #NMIBC #bladdercancer 👇

https://t.co/z0LMwCi4xf

[Sociedad Chilena de Urología @Urolchi]

📅 Les compartimos el calendario anual de SCHU, que incluye nuestras actividades académicas oficiales, además de las iniciativas patrocinadas y las internacionales.
Esperamos que puedan organizar y planificar sus agendas para que puedan participar en estas actividades.